Global vulvar cancer market is growing at a CAGR of 8.7% during forecast period 2022-2030

Market Highlights

The Vulvar Cancer market is anticipated to reach USD 824.5 Million by 2030 at 8.7% CAGR during the forecast period 2022-2030

Vulvar cancer is squamous cell skin cancer that occurs in elderly women. It is one of the rare type of cancer and the 4th common gynecologic cancer. Human papillomavirus infection, vulvar intraepithelial neoplasia, heavy cigarette smoking and many other things are major risk factors for this diseases. Beside these women suffering from HIV are also prone to develop vulvar cancer. The major driving factor for this market are increasing prevalence of vulvar cancer, continuous improvement in technology, growing consumer awareness and government’s initiatives. While high cost, availability of HPV vaccines and side effect of the therapy are the major restraining factor for the growth of this market.

As per region global vulvar cancer market is segmented into North America, Europe, Asia Pacific along with Middle East and Africa. Due to increasing prevalence of cancer, growing technological development and improvement in treatment all these are  responsible for making the North American vulvar cancer market as the largest market. Europe is the second largest market followed by Asia Pacific. Due to continuous development in the healthcare sector and continuously growing population  all these has led to growth of this market in Asia Pacific region.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of vulvar cancer Market Research Report

Segmentation:

Global vulvar cancer market is segmented on the basis of types which includes  adenocarcinoma, squamous cell carcinomas, melanoma, sarcoma and other. On the basis of treatment the market is  segmented into radiation therapy, chemotherapy, surgery and drugs treatment. Surgery is further sub segmented into excision, radical vulvectomy, partial vulvectomy and other. On the basis of end user it is segmented into hospitals, clinics, cancer research institutes and other

On application, chemotherapy is the most preferred treatment for vulvar cancer. However,  due to  side effects this segment may have slow growth and its  position will be taken by  surgical treatment.

Competitive Analysis

There are many players in the global vulvar cancer market, some of the key players are Abbott Diagnostics (US), Ono Pharmaceutical co ltd (Japan), PDS Biotechnology Corporation (US), Becton Deckinson and Company (US), Siemens Healthcare (Germany), Qiagen (Germany), ISA Pharmaceuticals B.V. (Netherland),  ORYX GmbH & Co. KG (Germany), PfizerInc(US), AmgenInc.(US), Johnson & Johnson (US), Novartis AG (Switzerland),F. Hoffmann-La Roche Ltd (Switzerland), Celgene Corporation (US), Merck&Co.(US) and many more.

Due to increasing prevalence of vulvar cancer,  globally many companies are in the race of inventing better treatment for vulvar cancer. Companies are using a trend of strategic alliance and acquisition to gain a high position in the market and minimize competition in the market.

Ono pharmaceutical co ltd, in 2017 has announced results of phase ½ clinical trial of opdivo (nivolumab). This drug has shown to give better results to  patients who are  suffering from vulvar cancer.

PDS Biotechnology Corporation, a biotechnological company is working on the development of new drug PDS0101 which is used for the treatment of vulvar cancer. In 2016, the company had submitted results obtained from phase I/IIA clinical study of PDS0101. The study had shown a strong position for this drug which has given a superior disease-specific T-cell response.

Qiagen, a provider of sample and assay technologies for molecular diagnostics, testing and pharmaceutical research. This company has introduce new in vitro method for detecting  human papillomavirus which causes vulvar cancer.

Novartis AG, a Swiss headquartered company has introduced Oncofocus®. Oncofocus® which is the oncology test used for detection of type of cancer and is considered as world’s most comprehensive precision oncology test which increases the chances of successful treatment.

Merck& Co. one of the leading pharmaceutical and research company has introduced Gardasil. This vaccine is approved by FDA for the treatment of vaginal and vulvar cancer. This vaccine is considered as the major achievement in the treatment of cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312